Flag of the European Union EU Clinical Trials Register Help

Clinical trials for boehringer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    904 result(s) found for: boehringer. Displaying page 16 of 46.
    «« First « Previous 12  13  14  15  16  17  18  19  20  Next» Last»»
    EudraCT Number: 2011-004660-30 Sponsor Protocol Number: 1237.14 Start Date*: 2012-01-18
    Sponsor Name:Boehringer Ingelheim b.v.
    Full Title: A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (F...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009032 Chronic obstructive lung disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) SE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018471-26 Sponsor Protocol Number: 205.380 Start Date*: 2010-10-12
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase II randomised, double-blind, placebo controlled, cross-over efficacy and safety comparison of three doses of tiotropium inhalation solution delivered via Respimat® inhaler (1.25, 2.5 and 5....
    Medical condition: moderate persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003555 Asthma bronchial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021945-29 Sponsor Protocol Number: 1200.98 Start Date*: 2011-02-18
    Sponsor Name:Boehringer Ingelheim
    Full Title: LUX-Breast 2;An open label, phase II trial of BIBW 2992 (afatinib) in patients with metastatic HER2-overexpressing breast cancer failing HER2-targeted treatment in the neoadjuvant and/or adjuvant t...
    Medical condition: HER2 - overexpressing breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000347-25 Sponsor Protocol Number: 1245.48 Start Date*: 2011-06-15
    Sponsor Name:Boehringer Ingelheim Finland KY
    Full Title: A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 12 weeks in hypertensive patients...
    Medical condition: Patients with type-2-diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) CZ (Completed) DE (Completed) EE (Completed) NL (Completed) DK (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2013-002622-23 Sponsor Protocol Number: 1301.4 Start Date*: 2014-06-24
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial
    Medical condition: moderately to severely active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) PT (Prematurely Ended) BG (Prematurely Ended) BE (Completed) DE (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000905-53 Sponsor Protocol Number: 1276.10 Start Date*: 2012-06-25
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: A randomised, double blind, placebo controlled, parallel group efficacy and safety study of oral administration of empagliflozin twice daily versus once daily in two different daily doses over 16 w...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    15.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed) DE (Completed) LT (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002522-29 Sponsor Protocol Number: 352.2046 Start Date*: 2008-10-08
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: A randomised, double-blind, active-controlled study to evaluate the impact of stepwise withdrawal of inhaled corticosteroid treatment in patients with severe to very severe chronic obstructive pulm...
    Medical condition: Chronic obstructive pulmonary disease (COPD). Enfermedad Pulmonar Obstructiva Crónica.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) BE (Completed) DE (Completed) GB (Completed) DK (Completed) NL (Completed) HU (Completed) IT (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-000808-41 Sponsor Protocol Number: 1237.11 Start Date*: 2013-08-27
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: Randomized, double-blind, double-dummy, active-controlled, 4 period complete cross-over study to compare the effect on lung function of 6 weeks once daily treatment with orally inhaled tiotropium+o...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed) CZ (Completed) BE (Completed) DK (Completed) SE (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004794-16 Sponsor Protocol Number: 1270.11 Start Date*: 2015-10-21
    Sponsor Name:SCS Boehringer Ingelheim Comm. V
    Full Title: An open label multicenter Phase Ib/II trial to determine the dose of BI 836826 in combination with gemcitabine and oxaliplatin (GemOx) and the efficacy of BI 836826 – GemOx versus rituximab ( R ) w...
    Medical condition: Patients with relapsed/refractory diffuse large B-cell lymphoma including transformed follicular lymphoma) who have been previously treated with an anti-CD20 monoclonal antibody (e.g. rituximab) in...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013788-21 Sponsor Protocol Number: 1199.35 Start Date*: 2010-04-28
    Sponsor Name:Boehringer Ingelheim España S.A.
    Full Title: Ensayo clínico de Fase II, abierto, y de extensión para evaluar la tolerabilidad a largo plazo, la seguridad y la eficacia de BIBF 1120 administrado por vía oral en pacientes con Fibrosis Pulmonar ...
    Medical condition: Fibrosis Pulmonar Idiopática
    Disease: Version SOC Term Classification Code Term Level
    12.1 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) FR (Completed) PT (Completed) IT (Completed) DE (Completed) IE (Completed) HU (Completed) CZ (Completed) BG (Completed) GB (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004011-41 Sponsor Protocol Number: 1280.8 Start Date*: 2015-10-16
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A Phase Ib/II, Multicentre, Open Label, Randomized Study of BI 836845 in Combination With Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Followin...
    Medical condition: Patients with metastatic castrate resistent prostate cancer (CRPC)
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-000096-80 Sponsor Protocol Number: 01 Start Date*: 2016-08-25
    Sponsor Name:University or Tromsø
    Full Title: Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST)
    Medical condition: Acute ischaemic stroke upon awakening ("wake-up stroke")
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) FI (Completed) GB (GB - no longer in EU/EEA) LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003718-25 Sponsor Protocol Number: 1302.3 Start Date*: 2016-04-26
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated locally advanced or metastatic colorectal...
    Medical condition: Previously untreated locally advanced or metastaticcolorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-002421-68 Sponsor Protocol Number: 1235.6 Start Date*: 2007-10-05
    Sponsor Name:Boehringer Ingelheim Ltd
    Full Title: An eight-week randomised, 3-arm, double-blind study to compare the safety and efficacy of the combination of telmisartan 40mg + amlodipine 10mg versus telmisartan 80mg + amlodipine 10mg versus amlo...
    Medical condition: essential hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) CZ (Completed) GB (Completed) AT (Completed) ES (Completed) BG (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-000935-18 Sponsor Protocol Number: UoL000841 Start Date*: 2012-06-28
    Sponsor Name:University of Liverpool [...]
    1. University of Liverpool
    2. Royal Liverpool and Broadgreen Hospitals NHS Trust
    Full Title: TAILoR – (TelmisArtan and InsuLin Resistance in HIV): A Dose-Ranging Phase II Randomised Open-Labelled Trial of Telmisartan as a strategy for the Reduction of Insulin Resistance in HIV-Positive Ind...
    Medical condition: Insulin resistance in HIV-positive patients treated with antiretroviral therapy
    Disease: Version SOC Term Classification Code Term Level
    17.0 10027433 - Metabolism and nutrition disorders 10022489 Insulin resistance PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-005015-28 Sponsor Protocol Number: 1289.6 Start Date*: 2014-10-31
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A phase II randomised, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of four orally administrated doses of BI 409306 during a 12-week treatment perio...
    Medical condition: Patients with schizophrenia on stable antispychotic treatment
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10039634 Schizophrenia residual LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005253-22 Sponsor Protocol Number: 1216.10 Start Date*: 2006-07-24
    Sponsor Name:Boehringer Ingelheim Austria GmbH
    Full Title: An open, randomised, clinical phase II trial in patients with unresectable advanced pancreatic cancer investigating the efficacy, safety, and pharmacokinetics of BI 2536 administered in repeated 3-...
    Medical condition: patients with unresectable (locally advanced or metastatic) pancreatic cancer, either chemonaive or after first-line chemotherapy with a gemciatbine based regimen
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000343-33 Sponsor Protocol Number: 248.641 Start Date*: 2009-07-29
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase III double-blind, double-dummy, placebo-controlled, 8 week fixed dose trial with pramipexole IR (Mirapex®, Mirapexin®, Pexola®, Sifrol®) 0.125 and 0.5 mg/day administered orally to investig...
    Medical condition: Tourette's Syndrome (TS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10044127 Tourette's syndrome LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000400-81 Sponsor Protocol Number: S308.2.008 Start Date*: 2009-04-03
    Sponsor Name:Solvay Pharmaceuticals BV
    Full Title: A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson’s D...
    Medical condition: Advanced Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003646-16 Sponsor Protocol Number: 1307.4 Start Date*: 2014-06-26
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A randomized, double-blind, placebo-controlled, parallel groups study to investigate the safety and tolerability, efficacy, pharmacokinetics and pharmacodynamics of three BI 187004 doses given onc...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 12  13  14  15  16  17  18  19  20  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 08:26:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA